Skip to main content
Erschienen in: Sleep and Breathing 2/2022

11.08.2021 | Basic Science • Letter to the Editors

Comments on “Increase in the circulating levels of malondialdehyde in patients with obstructive sleep apnea: a systematic review and meta-analysis”

verfasst von: Abolghasem Jouyban

Erschienen in: Sleep and Breathing | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Excerpt

I read with interest a systematic review and meta-analysis of Fadaei et al. [1] entitled “Increase in the circulating levels of malondialdehyde in patients with obstructive sleep apnea: a systematic review and meta-analysis”. The authors tried to pool available data to show the association between obstructive sleep apnea (OSA) and malondialdehyde (MDA) levels by meta-analysis of 14 published reports. MDA levels in the control groups varied in the range of 0.004 to 14.1 µmol/L (µM), and those of OSA groups were 0.0052 to 20.1 µM. Extreme heterogenecity was observed which could have originated from a number of possible sources: type of employed analytical method for determination of MDA (colorimetric, UV, spectroflourimetric and/or chromatographic methods), age of the sample donors in both control and OSA groups, their gender, and storage time of the samples. [2]. The large values of relative standard deviations in both control (varying between 17.4 to 312.8%) and OSA (varying between 0.5 to 62.2%) groups reveal that there are serious confounding factors affecting MDA levels in both groups. In addition, there are some points dealing with collecting MDA data reported in Table 2 of the review paper [1]; as examples, (1) MDA levels for control group (CG) and patient group (PG) were reported as 1.6 ± 0.4 and 2.6 ± 0.7 mM, whereas the reported data in the original paper (Ref #20 of [1]) were as 1.6 (1.5–1.8) and 2.6 (1.9–3.7) μM. Beside misquoted concentration unit of mM instead of μM, there is no straight and accurate procedure to calculate the standard deviations (as reported by Fadaei et al. [1]) from the range of MDA values. This is also the case for MDA data of Ref #26. A common way to estimate the standard deviation in these cases is dividing the range by 6, but this should be noted in the meta-analysis report. (2) The normal MDA values reported for the analytical method was 4.6–9.4 μM [3]; Asker et al. (Ref #28 of [1]) reported MDA levels for control group as 0.2 ± 0.1 Hmol/L! Interestingly, Hmol/L was a typographical error in the original paper of Asker et al., and it has been exactly repeated in Table 2 of the meta-analysis [1]. (3) Units of MDA were reported as nmol/L, mM or mmol/L, and μM and ng/mL. Using different concentration units poses difficulties in direct comparison of the data among various studies. We do not know if the values with different units were used in pooling the data or not? To facilitate the comparison, we convert all these data to μM and list in Table 1. (4) There were also typographical errors with MDA units of Refs. #20, #23, and #26. (5) There were more subgroups in the Yardim-Akaydin et al. study [18]; however, Fadaei et al. [1] discussed them in only three subgroups.
Table 1
Details of the reported data for malondialdehyde (MDA) in control (CG) and obstructive sleep apnea (PG) groups
1st author
Status
Ref.a
CG/PG
 
MDA ± SD (μM)
 
Differenceb
       
CG
PG
Measurement method
 
Ye
Mild
[24]
52/43
4.5 ± 1.2
4.6 ± 1.1
Kit 1
 = 
Ye
Moderate
[24]
52/39
4.5 ± 1.2
6.3 ± 2.1
Kit 1
 < 
Ye
Severe
[24]
52/45
4.5 ± 1.2
8.1 ± 2.9
Kit 1
 < 
Wang
Elderly
[16]
29/32
5.0 ± 0.7
6.2 ± 1.2
Kit 1
 < 
Wang
Non-elderly
[16]
23/51
4.1 ± 1.1
5.2 ± 1.5
Kit 1
 < 
Vatansever
Mild
[25]
24/9
0.9 ± 0.24c
1.0 ± 0.09c
HPLC
 = 
Vatansever
Severed
[25]
24/17
0.9 ± 0.24c
1.2 ± 0.29c
HPLC
 < 
Jurado-Gámez
 
[20]
46/23
1.6 (1.5–1.8)e
2.6 (1.9–3.7)e
Kit 2
 < 
Chen
Mild
[22]
20/23
0.004 (0.0032–0.0042)e
0.0052 (0.004–0.0055)e
Flourimetry
 
Chen
Moderate
[22]
20/21
0.004 (0.0032–0.0042)e
0.0059 (0.0049–0.0074)e
Flourimetry
 
Wysocka
Pre-OSA-negative
[26]
22/22
5.86 (4.91–6.24)e
6.88 (6.08–8.53)e
UV
 < 
Wysocka
Pre-OSA-positive
[26]
22/22
5.89 (4.95–7.22)e
6.20 (5.36–7.35)e
UV
 = 
Yardim-akaydin
Mild
[18]
25/28
2.2 ± 0.91
3.0 ± 1.18
HPLC
 < 
Yardim-akaydin
Moderate
[18]
25/30
2.2 ± 0.91
3.0 ± 0.89
HPLC
 < 
Yardim-akaydin
Severe
[18]
25/59
2.2 ± 0.91
3.3 ± 1.1
HPLC
 < 
Ntalapascha
 
[19]
13/18
6.45 ± 1.02
6.82 ± 0.32
Colorimetric
 = 
Araujo
 
[27]
20/33
0.05 ± 0.01f
0.06 ± 0.02f
Kit 3
 = 
Lu
 
[21]
31/62
14.1 ± 4.1
14.8 ± 6.3
Kit 3
 = 
Asker
 
[28]
30/30
0.179 ± 0.56
0.698 ± 0.434 g
UV
 < 
Li
Mild
[23]
33/41
4.6 ± 0.8 h
5.4 ± 1.3 h
Kit 1
 < 
Li
Moderate
[23]
33/40
4.6 ± 0.8 h
6.7 ± 0.7 h
Kit 1
 < 
Li
Severe
[23]
33/36
4.6 ± 0.8 h
7.3 ± 1.1 h
Kit 1
 < 
Cofta
Mild
[29]
26/26
2.7 ± 2.3 h
7.8 ± 1.9 h
Colorimetric
 < 
Cofta
Moderate
[29]
26/27
2.7 ± 2.3 h
13.1 ± 1.7 h
Colorimetric
 < 
Cofta
Severe
[29]
26/27
2.7 ± 2.3 h
18.2 ± 3.2 h
Colorimetric
 < 
Ekin
Mild
[30]
30/30
5.3 ± 1.1
7.6 ± 1.2
HPLC
 < 
Ekin
Moderate
[30]
30/30
5.3 ± 1.1
12.2 ± 3.1
HPLC
 < 
Ekin
Severe
[30]
30/30
5.3 ± 1.1
20.1 ± 5.6
HPLC
 < 
aReference numbers in the review paper [1]
b = non-significant difference and < means CG < PG
cIn the original work (Ref #25 of [1]), means standard errors were reported; we converted using SD = SE × √n
dIn the original work (Ref #25 of [1]), the subgroup called moderate-severe
eRange of variations were reported in the original works
fValues were converted to μM by dividing to 72.1 g/mol
gIn the original work (Ref #28 of [1]), it was reported as 0.698–0.434
hIn the original works, MDA values were shown graphically
Literatur
1.
Zurück zum Zitat Fadaei R, Safari-Faramani R, Hosseini H, Koushki M, Ahmadi R, Rostampour M, Khazaei H (2021) Increase in the circulating levels of malondialdehyde in patients with obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath in press https://doi.org/10.1007/s1132-021-02293-4 Fadaei R, Safari-Faramani R, Hosseini H, Koushki M, Ahmadi R, Rostampour M, Khazaei H (2021) Increase in the circulating levels of malondialdehyde in patients with obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath in press https://​doi.​org/​10.​1007/​s1132-021-02293-4
2.
Zurück zum Zitat Khoubnasabjafari M, Ansarin K, Jouyban A (2016) Critical review of malondialdehyde analysis in biological samples. Curr Pharm Anal 12:4–17CrossRef Khoubnasabjafari M, Ansarin K, Jouyban A (2016) Critical review of malondialdehyde analysis in biological samples. Curr Pharm Anal 12:4–17CrossRef
3.
Zurück zum Zitat Driessen C, Plomp RG, van der Spek PJ, Ince C, Kulik W, Mathijssen IM, Joosten KF (2013) Is there an effect of obstructive sleep apnea syndrome on oxidative stress and inflamatory parameters in patients with craniofacial anomalies? J Craniofac Surg 24:1908–1913CrossRef Driessen C, Plomp RG, van der Spek PJ, Ince C, Kulik W, Mathijssen IM, Joosten KF (2013) Is there an effect of obstructive sleep apnea syndrome on oxidative stress and inflamatory parameters in patients with craniofacial anomalies? J Craniofac Surg 24:1908–1913CrossRef
4.
Zurück zum Zitat Wade CR, van Rij AM (1989) Plasma malondialdehyde, lipid peroxides, and the thiobarbituric acid reaction. Clin Chem 35:336CrossRef Wade CR, van Rij AM (1989) Plasma malondialdehyde, lipid peroxides, and the thiobarbituric acid reaction. Clin Chem 35:336CrossRef
5.
Zurück zum Zitat Hackett C, Linley-Adams M, Lloyd B, Walker V (1988) Plasma malondialdehyde: a poor measure of in vivo lipid peroxidation. Clin Chem 34:208CrossRef Hackett C, Linley-Adams M, Lloyd B, Walker V (1988) Plasma malondialdehyde: a poor measure of in vivo lipid peroxidation. Clin Chem 34:208CrossRef
6.
Zurück zum Zitat Khoubnasabjafari M, Soleymani J, Jouyban A (2018) Avoid using spectrophotometric determination of malondialdehyde as a biomarker of oxidative stress. Biomark Med 12:551–554CrossRef Khoubnasabjafari M, Soleymani J, Jouyban A (2018) Avoid using spectrophotometric determination of malondialdehyde as a biomarker of oxidative stress. Biomark Med 12:551–554CrossRef
Metadaten
Titel
Comments on “Increase in the circulating levels of malondialdehyde in patients with obstructive sleep apnea: a systematic review and meta-analysis”
verfasst von
Abolghasem Jouyban
Publikationsdatum
11.08.2021
Verlag
Springer International Publishing
Erschienen in
Sleep and Breathing / Ausgabe 2/2022
Print ISSN: 1520-9512
Elektronische ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-021-02467-0

Weitere Artikel der Ausgabe 2/2022

Sleep and Breathing 2/2022 Zur Ausgabe

Sleep Breathing Physiology and Disorders • Original Article

Upper airway collapse characteristics in adult patients with OSA and previous tonsillectomy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.